Related Experiment Video
Updated: Jan 11, 2026
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Immunofluorescent characterization of Klotho and FGF23 in clear cell renal cell carcinoma: A pilot study
Anita Racetin1, Nela Kelam1, Merica Glavina Durdov2
1Department of Anatomy, Histology and Embryology, University of Split School of Medicine, Šoltanska 2A, Split, 21000, Croatia; Center for Translational Research in Biomedicine, University of Split School of Medicine, Šoltanska 2A, Split, 21000, Croatia.
Background/Objectives:
Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of renal malignancy, associated with poor prognosis in advanced stages. Emerging evidence highlights the potential tumor-suppressive role of the anti-aging protein Klotho (KL) and its cofactor, fibroblast growth factor 23 (FGF23), both of which are implicated in phosphate metabolism and cellular homeostasis.
Methods:
Using immunofluorescence and quantitative image analysis, we assessed KL and FGF23 protein levels in 20 ccRCC specimens stratified by tumor grade, alongside adjacent normal tissue. Publicly available RNA-seq and survival data from the TCGA-KIRC cohort were analyzed to complement our findings.
Results:
Immunofluorescence analysis of 20 ccRCC samples and matched normal tissues revealed consistently low Klotho expression with no significant differences across tumor grades. However, Kaplan-Meier survival analysis revealed that high KL mRNA expression was significantly associated with improved overall survival and disease-free survival, highlighting its role as a protective prognostic biomarker. Multivariate Cox regression confirmed KL as an independent predictor of better overall survival. In contrast, FGF23 protein levels were significantly elevated in ccRCC samples, particularly in high-grade tumors, despite minimal expression in control tissue and no significant differences at the mRNA level in the TCGA cohort. Notably, patients with detectable FGF23 expression had significantly worse survival outcomes, and multivariate analysis identified elevated FGF23 as an independent risk factor for poor prognosis. Age and tumor stage also remain strong prognostic determinants in our models.
Conclusions:
These findings suggest a dichotomous role for KL and FGF23 in ccRCC, with KL functioning as a favorable prognostic factor and FGF23 potentially contributing to disease progression and early relapse. Further mechanistic studies are warranted to elucidate their interplay and evaluate their utility as biomarkers or therapeutic targets in renal cancer.
